Skip to content

Study of the Efficacy and Tolerance of Light Therapy in Sensitive Skin

Study of the Efficacy and Tolerance of Light Therapy by Light-emitting Diode (LED) in Sensitive Skin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03279003
Acronym
SENSILED
Enrollment
30
Registered
2017-09-12
Start date
2018-06-22
Completion date
2018-11-12
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensitive Skin

Brief summary

Light-emitting diode (LED) light therapy is increasingly used successfully and without adverse effects in diabetic leg ulcer, chronic low back pain, chronic myofacial pain in the neck and in several dermatoses such as acne, Psoriasis, alopecia areata and skin rejuvenation. A Korean study conducted in 2013 suggested its effectiveness in patients with sensitive skin in connection with rosacea, acne, eczema. The objective of the study is to perform a study in subjects with a sensitive skin without associated dermatosis.

Detailed description

The objective of the study is to evaluate the efficacy of light-emitting diode therapy in subjects with sensitive skin and to assess pain improvement, evaluation of improvement in pruritus and evaluation of treatment tolerance.

Interventions

DEVICELED light

An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age greater than or equal to 18 years * Age less than or equal to 70 * Sensitive skin defined by a score ≥ 40 on the Sensiscale scale * Patient able to consent

Exclusion criteria

* Persons under 18 years of age or over. * Persons suffering from disorders of higher functions preventing comprehension of the questionnaire. * Pregnancy. * Analgesic or medication acting on the nervous system. * Other dermatosis of the face (example: rosacea, seborrheic dermatitis, acne ...). * Neurological or psychiatric illness. * A photosensitizing drug. * Refusal of patient * Patients under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of light therapy2 monthsThe improvement of sensitive skin symptoms will be measured by the Sensiscale scale

Secondary

MeasureTime frameDescription
Assessment of pain improvement2 monthsPain improvement will be done by self-evaluation of the patients, using a visual analog scale
Assessment of improvement in pruritus2 monthsThe improvement of pruritus will be done by self-evaluation of the patients, using a visual analog scale
Assessment of the tolerance2 monthsAt the end of the study, patients will be questioned about the possible occurrence of side effects listed in the patient's notebook during the 8 weeks of treatment.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026